Latest Quark Stories
WATERBURY, Vt., Dec. 1, 2010 /PRNewswire/ -- Experienced and aspiring travel bloggers can write to win a USD$54,000 expedition to the North Pole from Quark Expeditions. The prize is a trip for two aboard the world's most sophisticated and powerful nuclear-powered icebreaker to the top of the world.
After less than three weeks of heavy-ion running, the three experiments studying lead ion collisions at the LHC have already brought new insight into matter as it would have existed in the very first instants of the Universeâ€™s life.
The Large Hadron Collider (LHC) has taken new steps by smashing together lead ions instead of protons to create a "mini-Big Bang."
Researchers working at the worldâ€™s highest-energy particle accelerator on the Franco-Swiss border are nearly set to create the Big Bang on a miniature scale.
The Alpha Magnetic Spectrometer-2 (AMS) destined for the International Space Station already is collecting cosmic ray signatures, even as it sits in a work stand at the Space Station Processing Facility at NASA's Kennedy Space Center in Florida, said Prof Samuel Ting, the principal investigator for the program.
WATERBURY, Vt., Oct. 19 /PRNewswire/ -- The winner of the USD$45,000 prize in the Adventure with Julie competition sponsored by Quark Expeditions and SeaWorld, is blogging from an Emperor Penguin colony in Antarctica.
WATERBURY, Vt., Sept. 23 /PRNewswire/ -- Because travelers to the polar regions cannot try before they buy, Quark Expeditions has produced a number of video guides to provide a visual taste of the adventure that awaits. Two new guides were posted to the polar specialist's website.
A group of University of Toronto high-energy physicists, along with their 3,000 ATLAS colleagues, announced they have broken world records in the search for new particles as the first findings from the Large Hadron Collider (LHC) were presented July 26 in Paris, France.
The Large Hadron Collider (LHC) is giving physicists hopeful candidates in the hunt for the heaviest elementary particle known to science.
FREMONT, Calif., May 4 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California.